In Parkinson’s disease (PD) dopamine (DA) neurons located in the substantia nigra (SN) degenerate and die. Since all current therapies only treat symptoms, we hope to develop novel disease-modifying ...

Researchers have discovered a novel neurotrophic factor CDNF (Conserved Dopamine Neurotrophic Factor) that was shown to protect and even rescue damaged dopamine neurons in an experimental model of ...

Herantis Pharma Plc ("Herantis") announced today the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson`s disease and potentially other ...

Figure: Solution structure of human MANF protein. PDB ID: 2KVD [7]. Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte derived neurotrophic factor (MANF) form an evolutionary ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...

Parkinson's disease affects between 7 and 10 million people worldwide and the number of people diagnosed is soaring due to the ageing population. It affects dopamine-producing nerve cells in the brain ...

Herantis Pharma`s clinical study with CDNF in Parkinson`s disease authorized in Sweden Herantis Pharma Plc Company release 23 March 2017 at 12:30 pm The Medicines Agency of Sweden, MPA, has authorized ...

Global engineering technologies company, Renishaw, announces that its award-winning intraparenchymal drug delivery device has played a critical role in a joint Phase 1-2 clinical study with Herantis ...

The European Medicines Agency`s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the application of Herantis Pharma Plc ("Herantis") for orphan drug designation of ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...